Concept for the collection of routine practice data – Lifileucel (melanoma)

Project details

Project no.

A25-76

Commission

Commission awarded on 05.06.2025 by the Federal Joint Committee (GBA).

Report type

RPDC concept

Status

Withdrawn commission

Department/Division

Drug Assessment

Topic

Cancer

Note

Routine practice data collection (RPDC concept):

In the case of new drugs that have entered the health care system via a special marketing authorization or as a drug for the treatment of a rare disease, the study data at the time of marketing authorization are usually not very informative for the early benefit assessment. In these cases, according to the Law for More Safety in the Supply of Medicines (GSAV), the GBA can require the pharmaceutical company to collect routine practice data, including the associated analysis, for the benefit assessment. IQWiG prepares the concept for such a routine practice data collection on behalf of the GBA.

Connected Projects

1. Search for disease registries

   Unresectable or metastatic melanoma; assessment according to §35a Social Code Book V; search for disease registries

   Project no.

   I25-02

   Last updated

   11.06.2025

   Status: Commission completed